- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Urgent action needed to lessen the future impact of atrial fibrillation
2 June 2015 • Author: Victoria White
Launched in Brussels at the start of Heart Rhythm Week (1-7 June 2015), the Future of Anticoagulation Report highlights that urgent action is critical to lessening the potential impact of atrial fibrillation.
With an aging population in Europe and the prevalence of atrial fibrillation expected to double in the continent by 2060, atrial fibrillation looks likely to become a future health issue for millions of people in Europe.
Researched and written by RAND Europe, with contributions from a panel of leading European medical, patient group and health economic experts, the Future of Anticoagulation Report explores how decisions made today can change and reshape the landscape of tomorrow and have the potential to make a significant difference in changing the direction of this disease in terms of prevalence and impact.
Atrial fibrillation is associated with a five times higher risk of stroke
Atrial fibrillation, a disorder of the rhythm of the heart, is expected to be a leading health burden in the EU in the coming years. It is the most common sustained arrhythmia in the general population affecting approximately 1.5-2% of the population in the developed world. A heart rhythm disorder may remain ‘silent’, asymptomatic and undiscovered for months or even years. However, its eventual consequences can be very damaging and are associated with significant morbidities and mortality.
Atrial fibrillation is associated with a five times higher risk of stroke and a three times higher risk of heart failure. Strokes that result from atrial fibrillation are more severe and are associated with a high risk of mortality (32.8%) and with a 50% probability of remaining disabled or handicapped within 3 months of having a stroke. Therefore, the increasing number of adults with atrial fibrillation will have major public health implications across Europe over the forthcoming decades. Although new medical therapies have been developed and recommendations for diagnosis and treatments aligned in Europe in the last few years, atrial fibrillation is still under or not treated in many cases.
The Future of Anticoagulation Report outlines three primary short-term recommendations:
- improve atrial fibrillation awareness amongst the public and policy makers,
- support education about atrial fibrillation management for healthcare professionals and patients,
- maintain atrial fibrillation related research across the health services to be able to monitor what works best in terms of healthcare interventions.
“This report is a wake-up call for healthcare professionals and policy makers across Europe to work together to better manage atrial fibrillation, as its burden looks set to double as our population ages,” explains Professor John Camm, Chair of the Future of Anticoagulation Steering Committee, Professor of Clinical Cardiology, St. George’s, University of London and Professor of Cardiology, Imperial College London, United Kingdom. “I would especially like to highlight that we need to improve healthcare policies related to atrial fibrillation, including improving diagnosis and supporting earlier treatment interventions, such as effective modern anticoagulant medicines, to ensure that we can ultimately prevent avoidable deaths across the continent.”
The two main goals of the study were to develop an evidence base on the current reality of atrial fibrillation-related anticoagulation management in six European countries and to develop an understanding of actions that could be taken today to improve the outlook for future atrial fibrillation management. The methods of research comprised a literature review and assessment, and 60 interviews carried out with a range of experts representing various stakeholder groups such as healthcare professionals, patient representatives and policymakers. In addition, a Steering Committee and an international patient group were actively involved in the development of the report.
There will be significant human and economic consequences in coming years if clear steps are not take to stem the rising burden of atrial fibrillation
“Through the research we conducted and the insights gathered from the broader atrial fibrillation community, one overriding message has crystallised: there will be significant human and economic consequences in the coming years if clear steps are not taken now to stem the rising burden of atrial fibrillation,” commented Professor Joanna Chataway, Research Group Director, Innovation, Health and Science, RAND Europe.
Detecting an irregular heart rhythm might be as simple as a manual pulse check, with any unusual rhythm verified with an electrocardiogram (ECG). Trudie C. Lobban MBE, Founder & CEO of Atrial Fibrillation Association (AFA) explained, “Lives can be saved if only people begin to regularly check their pulse. Early diagnosis is more challenging if few people know about atrial fibrillation or its symptoms, and if atrial fibrillation goes undiagnosed, opportunities for earlier interventions and treatment to prevent atrial fibrillation-related stroke are missed entirely. The Atrial Fibrillation Association welcomes this timely report that underscores how important it is to Detect, Protect and Correct heart rhythm disorders across the EU.”
The report’s longer-term recommendations include:
- taking a longer-term view in decisions on spending for atrial fibrillation awareness, education, care and management that are considered vital for improving health outcomes;
- there is a need for continued improvement in patient stratification (such as based on biomarkers or health imaging) that can lead to enhanced personalisation of treatment and medical care;
- there needs to be greater interaction among primary, community, secondary and tertiary healthcare professionals to enable greater knowledge sharing and more whole-patient approaches to care; enhancing monitoring via developments in devices and data is also needed to maximise benefits of atrial fibrillation management.
The Future of Anticoagulation initiative was supported financially and in kind by Daiichi Sankyo Europe.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics